Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 3

1.

Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.

Ramalingam SS, Belani CP, Ruel C, Frankel P, Gitlitz B, Koczywas M, Espinoza-Delgado I, Gandara D.

J Thorac Oncol. 2009 Jan;4(1):97-101. doi: 10.1097/JTO.0b013e318191520c.

2.

The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.

Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care..

J Thorac Oncol. 2006 Jul;1(6):591-601. Review.

3.

Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.

Paik PK, Krug LM.

J Thorac Oncol. 2010 Feb;5(2):275-9. doi: 10.1097/JTO.0b013e3181c5e366. Review.

Supplemental Content

Support Center